Research ArticleAccepted Article
Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology
Dorcas E. Beaton, Lara J. Maxwell, Beverley J. Shea, George A. Wells, Maarten Boers, Shawna Grosskleg, Clifton O. Bingham III, Philip G. Conaghan, Maria Antonietta D’Agostino, Maarten de Wit, Laure Gossec, Lyn M. March, Lee S. Simon, Jasvinder A. Singh, Vibeke Strand and Peter Tugwell
The Journal of Rheumatology February 2019, jrheum.181218; DOI: https://doi.org/10.3899/jrheum.181218
Dorcas E. Beaton
Institute for Work & Health and Institute for Health Policy Management and Evaluation, University of Toronto, Toronto ON Canada; Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, ON, Canada; Centre for Practice-Changing Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada; University of Ottawa, Ottawa, ON, Canada; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada; Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, 92100 Boulogne-Billancourt; INSERM U1173, Laboratoire d’Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, 78180 Saint-Quentin en Yvelines; France Department of Medical Humanities, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands; Sorbonne Université, Paris France; Pitié Salpêtrière hospital, APHP, Rheumatology department, Paris, France; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St Leonards, Australia; Medicine Service, VA Medical Center, Birmingham, AL , USA; Department of Medicine, School of Medicine, University of Alabama, Birmingham, AL, USA; Division of Epidemiology, School of Public Health, University of Alabama, Birmingham, AL, USA SDG LLC, Cambridge, MA, USA; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto CA, USA; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health , Faculty of Medicine, University of Ottawa ; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada. In kind support from Knowledge Transfer and Exchange team and the Measurement Sciences group at the Institute for Work & Health is acknowledged for the development of the OMERACT Way graphics and input into the methods used. PGC is funded in part by the National Institute of Health Research (NIHR) Leeds Biomedical Research Centre. This article presents independent research funded by the NIHR. The views expressed are those of the authors and not necessarily those of the National Health Services (NHS), the NIHR or the Department of Health. JAS has received consultant fees from Crealta/Horizon, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the University of Alabama Birmingham (UAB) Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS served as a member of the American College of Rheumatology's (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and the co-chair of the ACR Criteria and Response Criteria subcommittee. LMM is a Principal Investigator on the Australian Rheumatology Association Database that has received arms-length funding from 4 companies (Abbvie Australasia Ltd, Pfizer Australia, Janssen Australia, Eli Lilly Australia). PT is [unpaid] Chair of the Management SubCommittee of the Executive committee of a registered non-profit independent medical research organization, OMERACT, whose goal is to improve and advance the health outcomes for patients suffering from musculoskeletal conditions. OMERACT receives unrestricted educational grants from the American College of Rheumatology, European League of Rheumatology and several pharmaceutical companies listed below which is used to support fellows, international patient groups and support a major international biennial conference which results in many peer reviewed publications; Abbvie Amgen, Astra Zeneca, Bristol Myers Squibb, Celgene, Centrexion, EliLilly, Genentech/Roche, Gruenthal, Horizon Pharma Inc., Janssen, Novartis, Pfizer, Quintiles, UCB Group. PT is an independent Committee Member for clinical trial Data Safety Monitoring Boards for FDA approved trials for UCB Biopharma GmbH & SPRL, Parexel International, Prahealth Sciences and the Reformulary Group. PT is an advisory board member for the Canadian Reformulary Group Inc., a company that reviews the evidence for health insurance companies employer drug plans. Address correspondence to Dorcas Beaton BScOT, PhD, Senior Scientist, Institute for Work & Health, 481 University Avenue, Toronto, ON Canada. Email: dbeaton@iwh.on.ca
Lara J. Maxwell
Institute for Work & Health and Institute for Health Policy Management and Evaluation, University of Toronto, Toronto ON Canada; Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, ON, Canada; Centre for Practice-Changing Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada; University of Ottawa, Ottawa, ON, Canada; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada; Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, 92100 Boulogne-Billancourt; INSERM U1173, Laboratoire d’Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, 78180 Saint-Quentin en Yvelines; France Department of Medical Humanities, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands; Sorbonne Université, Paris France; Pitié Salpêtrière hospital, APHP, Rheumatology department, Paris, France; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St Leonards, Australia; Medicine Service, VA Medical Center, Birmingham, AL , USA; Department of Medicine, School of Medicine, University of Alabama, Birmingham, AL, USA; Division of Epidemiology, School of Public Health, University of Alabama, Birmingham, AL, USA SDG LLC, Cambridge, MA, USA; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto CA, USA; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health , Faculty of Medicine, University of Ottawa ; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada. In kind support from Knowledge Transfer and Exchange team and the Measurement Sciences group at the Institute for Work & Health is acknowledged for the development of the OMERACT Way graphics and input into the methods used. PGC is funded in part by the National Institute of Health Research (NIHR) Leeds Biomedical Research Centre. This article presents independent research funded by the NIHR. The views expressed are those of the authors and not necessarily those of the National Health Services (NHS), the NIHR or the Department of Health. JAS has received consultant fees from Crealta/Horizon, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the University of Alabama Birmingham (UAB) Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS served as a member of the American College of Rheumatology's (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and the co-chair of the ACR Criteria and Response Criteria subcommittee. LMM is a Principal Investigator on the Australian Rheumatology Association Database that has received arms-length funding from 4 companies (Abbvie Australasia Ltd, Pfizer Australia, Janssen Australia, Eli Lilly Australia). PT is [unpaid] Chair of the Management SubCommittee of the Executive committee of a registered non-profit independent medical research organization, OMERACT, whose goal is to improve and advance the health outcomes for patients suffering from musculoskeletal conditions. OMERACT receives unrestricted educational grants from the American College of Rheumatology, European League of Rheumatology and several pharmaceutical companies listed below which is used to support fellows, international patient groups and support a major international biennial conference which results in many peer reviewed publications; Abbvie Amgen, Astra Zeneca, Bristol Myers Squibb, Celgene, Centrexion, EliLilly, Genentech/Roche, Gruenthal, Horizon Pharma Inc., Janssen, Novartis, Pfizer, Quintiles, UCB Group. PT is an independent Committee Member for clinical trial Data Safety Monitoring Boards for FDA approved trials for UCB Biopharma GmbH & SPRL, Parexel International, Prahealth Sciences and the Reformulary Group. PT is an advisory board member for the Canadian Reformulary Group Inc., a company that reviews the evidence for health insurance companies employer drug plans. Address correspondence to Dorcas Beaton BScOT, PhD, Senior Scientist, Institute for Work & Health, 481 University Avenue, Toronto, ON Canada. Email: dbeaton@iwh.on.ca
Beverley J. Shea
Institute for Work & Health and Institute for Health Policy Management and Evaluation, University of Toronto, Toronto ON Canada; Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, ON, Canada; Centre for Practice-Changing Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada; University of Ottawa, Ottawa, ON, Canada; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada; Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, 92100 Boulogne-Billancourt; INSERM U1173, Laboratoire d’Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, 78180 Saint-Quentin en Yvelines; France Department of Medical Humanities, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands; Sorbonne Université, Paris France; Pitié Salpêtrière hospital, APHP, Rheumatology department, Paris, France; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St Leonards, Australia; Medicine Service, VA Medical Center, Birmingham, AL , USA; Department of Medicine, School of Medicine, University of Alabama, Birmingham, AL, USA; Division of Epidemiology, School of Public Health, University of Alabama, Birmingham, AL, USA SDG LLC, Cambridge, MA, USA; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto CA, USA; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health , Faculty of Medicine, University of Ottawa ; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada. In kind support from Knowledge Transfer and Exchange team and the Measurement Sciences group at the Institute for Work & Health is acknowledged for the development of the OMERACT Way graphics and input into the methods used. PGC is funded in part by the National Institute of Health Research (NIHR) Leeds Biomedical Research Centre. This article presents independent research funded by the NIHR. The views expressed are those of the authors and not necessarily those of the National Health Services (NHS), the NIHR or the Department of Health. JAS has received consultant fees from Crealta/Horizon, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the University of Alabama Birmingham (UAB) Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS served as a member of the American College of Rheumatology's (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and the co-chair of the ACR Criteria and Response Criteria subcommittee. LMM is a Principal Investigator on the Australian Rheumatology Association Database that has received arms-length funding from 4 companies (Abbvie Australasia Ltd, Pfizer Australia, Janssen Australia, Eli Lilly Australia). PT is [unpaid] Chair of the Management SubCommittee of the Executive committee of a registered non-profit independent medical research organization, OMERACT, whose goal is to improve and advance the health outcomes for patients suffering from musculoskeletal conditions. OMERACT receives unrestricted educational grants from the American College of Rheumatology, European League of Rheumatology and several pharmaceutical companies listed below which is used to support fellows, international patient groups and support a major international biennial conference which results in many peer reviewed publications; Abbvie Amgen, Astra Zeneca, Bristol Myers Squibb, Celgene, Centrexion, EliLilly, Genentech/Roche, Gruenthal, Horizon Pharma Inc., Janssen, Novartis, Pfizer, Quintiles, UCB Group. PT is an independent Committee Member for clinical trial Data Safety Monitoring Boards for FDA approved trials for UCB Biopharma GmbH & SPRL, Parexel International, Prahealth Sciences and the Reformulary Group. PT is an advisory board member for the Canadian Reformulary Group Inc., a company that reviews the evidence for health insurance companies employer drug plans. Address correspondence to Dorcas Beaton BScOT, PhD, Senior Scientist, Institute for Work & Health, 481 University Avenue, Toronto, ON Canada. Email: dbeaton@iwh.on.ca
George A. Wells
Institute for Work & Health and Institute for Health Policy Management and Evaluation, University of Toronto, Toronto ON Canada; Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, ON, Canada; Centre for Practice-Changing Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada; University of Ottawa, Ottawa, ON, Canada; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada; Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, 92100 Boulogne-Billancourt; INSERM U1173, Laboratoire d’Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, 78180 Saint-Quentin en Yvelines; France Department of Medical Humanities, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands; Sorbonne Université, Paris France; Pitié Salpêtrière hospital, APHP, Rheumatology department, Paris, France; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St Leonards, Australia; Medicine Service, VA Medical Center, Birmingham, AL , USA; Department of Medicine, School of Medicine, University of Alabama, Birmingham, AL, USA; Division of Epidemiology, School of Public Health, University of Alabama, Birmingham, AL, USA SDG LLC, Cambridge, MA, USA; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto CA, USA; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health , Faculty of Medicine, University of Ottawa ; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada. In kind support from Knowledge Transfer and Exchange team and the Measurement Sciences group at the Institute for Work & Health is acknowledged for the development of the OMERACT Way graphics and input into the methods used. PGC is funded in part by the National Institute of Health Research (NIHR) Leeds Biomedical Research Centre. This article presents independent research funded by the NIHR. The views expressed are those of the authors and not necessarily those of the National Health Services (NHS), the NIHR or the Department of Health. JAS has received consultant fees from Crealta/Horizon, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the University of Alabama Birmingham (UAB) Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS served as a member of the American College of Rheumatology's (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and the co-chair of the ACR Criteria and Response Criteria subcommittee. LMM is a Principal Investigator on the Australian Rheumatology Association Database that has received arms-length funding from 4 companies (Abbvie Australasia Ltd, Pfizer Australia, Janssen Australia, Eli Lilly Australia). PT is [unpaid] Chair of the Management SubCommittee of the Executive committee of a registered non-profit independent medical research organization, OMERACT, whose goal is to improve and advance the health outcomes for patients suffering from musculoskeletal conditions. OMERACT receives unrestricted educational grants from the American College of Rheumatology, European League of Rheumatology and several pharmaceutical companies listed below which is used to support fellows, international patient groups and support a major international biennial conference which results in many peer reviewed publications; Abbvie Amgen, Astra Zeneca, Bristol Myers Squibb, Celgene, Centrexion, EliLilly, Genentech/Roche, Gruenthal, Horizon Pharma Inc., Janssen, Novartis, Pfizer, Quintiles, UCB Group. PT is an independent Committee Member for clinical trial Data Safety Monitoring Boards for FDA approved trials for UCB Biopharma GmbH & SPRL, Parexel International, Prahealth Sciences and the Reformulary Group. PT is an advisory board member for the Canadian Reformulary Group Inc., a company that reviews the evidence for health insurance companies employer drug plans. Address correspondence to Dorcas Beaton BScOT, PhD, Senior Scientist, Institute for Work & Health, 481 University Avenue, Toronto, ON Canada. Email: dbeaton@iwh.on.ca
Maarten Boers
Institute for Work & Health and Institute for Health Policy Management and Evaluation, University of Toronto, Toronto ON Canada; Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, ON, Canada; Centre for Practice-Changing Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada; University of Ottawa, Ottawa, ON, Canada; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada; Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, 92100 Boulogne-Billancourt; INSERM U1173, Laboratoire d’Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, 78180 Saint-Quentin en Yvelines; France Department of Medical Humanities, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands; Sorbonne Université, Paris France; Pitié Salpêtrière hospital, APHP, Rheumatology department, Paris, France; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St Leonards, Australia; Medicine Service, VA Medical Center, Birmingham, AL , USA; Department of Medicine, School of Medicine, University of Alabama, Birmingham, AL, USA; Division of Epidemiology, School of Public Health, University of Alabama, Birmingham, AL, USA SDG LLC, Cambridge, MA, USA; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto CA, USA; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health , Faculty of Medicine, University of Ottawa ; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada. In kind support from Knowledge Transfer and Exchange team and the Measurement Sciences group at the Institute for Work & Health is acknowledged for the development of the OMERACT Way graphics and input into the methods used. PGC is funded in part by the National Institute of Health Research (NIHR) Leeds Biomedical Research Centre. This article presents independent research funded by the NIHR. The views expressed are those of the authors and not necessarily those of the National Health Services (NHS), the NIHR or the Department of Health. JAS has received consultant fees from Crealta/Horizon, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the University of Alabama Birmingham (UAB) Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS served as a member of the American College of Rheumatology's (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and the co-chair of the ACR Criteria and Response Criteria subcommittee. LMM is a Principal Investigator on the Australian Rheumatology Association Database that has received arms-length funding from 4 companies (Abbvie Australasia Ltd, Pfizer Australia, Janssen Australia, Eli Lilly Australia). PT is [unpaid] Chair of the Management SubCommittee of the Executive committee of a registered non-profit independent medical research organization, OMERACT, whose goal is to improve and advance the health outcomes for patients suffering from musculoskeletal conditions. OMERACT receives unrestricted educational grants from the American College of Rheumatology, European League of Rheumatology and several pharmaceutical companies listed below which is used to support fellows, international patient groups and support a major international biennial conference which results in many peer reviewed publications; Abbvie Amgen, Astra Zeneca, Bristol Myers Squibb, Celgene, Centrexion, EliLilly, Genentech/Roche, Gruenthal, Horizon Pharma Inc., Janssen, Novartis, Pfizer, Quintiles, UCB Group. PT is an independent Committee Member for clinical trial Data Safety Monitoring Boards for FDA approved trials for UCB Biopharma GmbH & SPRL, Parexel International, Prahealth Sciences and the Reformulary Group. PT is an advisory board member for the Canadian Reformulary Group Inc., a company that reviews the evidence for health insurance companies employer drug plans. Address correspondence to Dorcas Beaton BScOT, PhD, Senior Scientist, Institute for Work & Health, 481 University Avenue, Toronto, ON Canada. Email: dbeaton@iwh.on.ca
Shawna Grosskleg
Institute for Work & Health and Institute for Health Policy Management and Evaluation, University of Toronto, Toronto ON Canada; Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, ON, Canada; Centre for Practice-Changing Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada; University of Ottawa, Ottawa, ON, Canada; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada; Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, 92100 Boulogne-Billancourt; INSERM U1173, Laboratoire d’Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, 78180 Saint-Quentin en Yvelines; France Department of Medical Humanities, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands; Sorbonne Université, Paris France; Pitié Salpêtrière hospital, APHP, Rheumatology department, Paris, France; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St Leonards, Australia; Medicine Service, VA Medical Center, Birmingham, AL , USA; Department of Medicine, School of Medicine, University of Alabama, Birmingham, AL, USA; Division of Epidemiology, School of Public Health, University of Alabama, Birmingham, AL, USA SDG LLC, Cambridge, MA, USA; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto CA, USA; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health , Faculty of Medicine, University of Ottawa ; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada. In kind support from Knowledge Transfer and Exchange team and the Measurement Sciences group at the Institute for Work & Health is acknowledged for the development of the OMERACT Way graphics and input into the methods used. PGC is funded in part by the National Institute of Health Research (NIHR) Leeds Biomedical Research Centre. This article presents independent research funded by the NIHR. The views expressed are those of the authors and not necessarily those of the National Health Services (NHS), the NIHR or the Department of Health. JAS has received consultant fees from Crealta/Horizon, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the University of Alabama Birmingham (UAB) Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS served as a member of the American College of Rheumatology's (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and the co-chair of the ACR Criteria and Response Criteria subcommittee. LMM is a Principal Investigator on the Australian Rheumatology Association Database that has received arms-length funding from 4 companies (Abbvie Australasia Ltd, Pfizer Australia, Janssen Australia, Eli Lilly Australia). PT is [unpaid] Chair of the Management SubCommittee of the Executive committee of a registered non-profit independent medical research organization, OMERACT, whose goal is to improve and advance the health outcomes for patients suffering from musculoskeletal conditions. OMERACT receives unrestricted educational grants from the American College of Rheumatology, European League of Rheumatology and several pharmaceutical companies listed below which is used to support fellows, international patient groups and support a major international biennial conference which results in many peer reviewed publications; Abbvie Amgen, Astra Zeneca, Bristol Myers Squibb, Celgene, Centrexion, EliLilly, Genentech/Roche, Gruenthal, Horizon Pharma Inc., Janssen, Novartis, Pfizer, Quintiles, UCB Group. PT is an independent Committee Member for clinical trial Data Safety Monitoring Boards for FDA approved trials for UCB Biopharma GmbH & SPRL, Parexel International, Prahealth Sciences and the Reformulary Group. PT is an advisory board member for the Canadian Reformulary Group Inc., a company that reviews the evidence for health insurance companies employer drug plans. Address correspondence to Dorcas Beaton BScOT, PhD, Senior Scientist, Institute for Work & Health, 481 University Avenue, Toronto, ON Canada. Email: dbeaton@iwh.on.ca
Clifton O. Bingham III
Institute for Work & Health and Institute for Health Policy Management and Evaluation, University of Toronto, Toronto ON Canada; Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, ON, Canada; Centre for Practice-Changing Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada; University of Ottawa, Ottawa, ON, Canada; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada; Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, 92100 Boulogne-Billancourt; INSERM U1173, Laboratoire d’Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, 78180 Saint-Quentin en Yvelines; France Department of Medical Humanities, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands; Sorbonne Université, Paris France; Pitié Salpêtrière hospital, APHP, Rheumatology department, Paris, France; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St Leonards, Australia; Medicine Service, VA Medical Center, Birmingham, AL , USA; Department of Medicine, School of Medicine, University of Alabama, Birmingham, AL, USA; Division of Epidemiology, School of Public Health, University of Alabama, Birmingham, AL, USA SDG LLC, Cambridge, MA, USA; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto CA, USA; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health , Faculty of Medicine, University of Ottawa ; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada. In kind support from Knowledge Transfer and Exchange team and the Measurement Sciences group at the Institute for Work & Health is acknowledged for the development of the OMERACT Way graphics and input into the methods used. PGC is funded in part by the National Institute of Health Research (NIHR) Leeds Biomedical Research Centre. This article presents independent research funded by the NIHR. The views expressed are those of the authors and not necessarily those of the National Health Services (NHS), the NIHR or the Department of Health. JAS has received consultant fees from Crealta/Horizon, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the University of Alabama Birmingham (UAB) Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS served as a member of the American College of Rheumatology's (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and the co-chair of the ACR Criteria and Response Criteria subcommittee. LMM is a Principal Investigator on the Australian Rheumatology Association Database that has received arms-length funding from 4 companies (Abbvie Australasia Ltd, Pfizer Australia, Janssen Australia, Eli Lilly Australia). PT is [unpaid] Chair of the Management SubCommittee of the Executive committee of a registered non-profit independent medical research organization, OMERACT, whose goal is to improve and advance the health outcomes for patients suffering from musculoskeletal conditions. OMERACT receives unrestricted educational grants from the American College of Rheumatology, European League of Rheumatology and several pharmaceutical companies listed below which is used to support fellows, international patient groups and support a major international biennial conference which results in many peer reviewed publications; Abbvie Amgen, Astra Zeneca, Bristol Myers Squibb, Celgene, Centrexion, EliLilly, Genentech/Roche, Gruenthal, Horizon Pharma Inc., Janssen, Novartis, Pfizer, Quintiles, UCB Group. PT is an independent Committee Member for clinical trial Data Safety Monitoring Boards for FDA approved trials for UCB Biopharma GmbH & SPRL, Parexel International, Prahealth Sciences and the Reformulary Group. PT is an advisory board member for the Canadian Reformulary Group Inc., a company that reviews the evidence for health insurance companies employer drug plans. Address correspondence to Dorcas Beaton BScOT, PhD, Senior Scientist, Institute for Work & Health, 481 University Avenue, Toronto, ON Canada. Email: dbeaton@iwh.on.ca
Philip G. Conaghan
Institute for Work & Health and Institute for Health Policy Management and Evaluation, University of Toronto, Toronto ON Canada; Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, ON, Canada; Centre for Practice-Changing Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada; University of Ottawa, Ottawa, ON, Canada; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada; Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, 92100 Boulogne-Billancourt; INSERM U1173, Laboratoire d’Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, 78180 Saint-Quentin en Yvelines; France Department of Medical Humanities, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands; Sorbonne Université, Paris France; Pitié Salpêtrière hospital, APHP, Rheumatology department, Paris, France; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St Leonards, Australia; Medicine Service, VA Medical Center, Birmingham, AL , USA; Department of Medicine, School of Medicine, University of Alabama, Birmingham, AL, USA; Division of Epidemiology, School of Public Health, University of Alabama, Birmingham, AL, USA SDG LLC, Cambridge, MA, USA; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto CA, USA; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health , Faculty of Medicine, University of Ottawa ; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada. In kind support from Knowledge Transfer and Exchange team and the Measurement Sciences group at the Institute for Work & Health is acknowledged for the development of the OMERACT Way graphics and input into the methods used. PGC is funded in part by the National Institute of Health Research (NIHR) Leeds Biomedical Research Centre. This article presents independent research funded by the NIHR. The views expressed are those of the authors and not necessarily those of the National Health Services (NHS), the NIHR or the Department of Health. JAS has received consultant fees from Crealta/Horizon, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the University of Alabama Birmingham (UAB) Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS served as a member of the American College of Rheumatology's (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and the co-chair of the ACR Criteria and Response Criteria subcommittee. LMM is a Principal Investigator on the Australian Rheumatology Association Database that has received arms-length funding from 4 companies (Abbvie Australasia Ltd, Pfizer Australia, Janssen Australia, Eli Lilly Australia). PT is [unpaid] Chair of the Management SubCommittee of the Executive committee of a registered non-profit independent medical research organization, OMERACT, whose goal is to improve and advance the health outcomes for patients suffering from musculoskeletal conditions. OMERACT receives unrestricted educational grants from the American College of Rheumatology, European League of Rheumatology and several pharmaceutical companies listed below which is used to support fellows, international patient groups and support a major international biennial conference which results in many peer reviewed publications; Abbvie Amgen, Astra Zeneca, Bristol Myers Squibb, Celgene, Centrexion, EliLilly, Genentech/Roche, Gruenthal, Horizon Pharma Inc., Janssen, Novartis, Pfizer, Quintiles, UCB Group. PT is an independent Committee Member for clinical trial Data Safety Monitoring Boards for FDA approved trials for UCB Biopharma GmbH & SPRL, Parexel International, Prahealth Sciences and the Reformulary Group. PT is an advisory board member for the Canadian Reformulary Group Inc., a company that reviews the evidence for health insurance companies employer drug plans. Address correspondence to Dorcas Beaton BScOT, PhD, Senior Scientist, Institute for Work & Health, 481 University Avenue, Toronto, ON Canada. Email: dbeaton@iwh.on.ca
Maria Antonietta D’Agostino
Institute for Work & Health and Institute for Health Policy Management and Evaluation, University of Toronto, Toronto ON Canada; Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, ON, Canada; Centre for Practice-Changing Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada; University of Ottawa, Ottawa, ON, Canada; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada; Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, 92100 Boulogne-Billancourt; INSERM U1173, Laboratoire d’Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, 78180 Saint-Quentin en Yvelines; France Department of Medical Humanities, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands; Sorbonne Université, Paris France; Pitié Salpêtrière hospital, APHP, Rheumatology department, Paris, France; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St Leonards, Australia; Medicine Service, VA Medical Center, Birmingham, AL , USA; Department of Medicine, School of Medicine, University of Alabama, Birmingham, AL, USA; Division of Epidemiology, School of Public Health, University of Alabama, Birmingham, AL, USA SDG LLC, Cambridge, MA, USA; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto CA, USA; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health , Faculty of Medicine, University of Ottawa ; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada. In kind support from Knowledge Transfer and Exchange team and the Measurement Sciences group at the Institute for Work & Health is acknowledged for the development of the OMERACT Way graphics and input into the methods used. PGC is funded in part by the National Institute of Health Research (NIHR) Leeds Biomedical Research Centre. This article presents independent research funded by the NIHR. The views expressed are those of the authors and not necessarily those of the National Health Services (NHS), the NIHR or the Department of Health. JAS has received consultant fees from Crealta/Horizon, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the University of Alabama Birmingham (UAB) Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS served as a member of the American College of Rheumatology's (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and the co-chair of the ACR Criteria and Response Criteria subcommittee. LMM is a Principal Investigator on the Australian Rheumatology Association Database that has received arms-length funding from 4 companies (Abbvie Australasia Ltd, Pfizer Australia, Janssen Australia, Eli Lilly Australia). PT is [unpaid] Chair of the Management SubCommittee of the Executive committee of a registered non-profit independent medical research organization, OMERACT, whose goal is to improve and advance the health outcomes for patients suffering from musculoskeletal conditions. OMERACT receives unrestricted educational grants from the American College of Rheumatology, European League of Rheumatology and several pharmaceutical companies listed below which is used to support fellows, international patient groups and support a major international biennial conference which results in many peer reviewed publications; Abbvie Amgen, Astra Zeneca, Bristol Myers Squibb, Celgene, Centrexion, EliLilly, Genentech/Roche, Gruenthal, Horizon Pharma Inc., Janssen, Novartis, Pfizer, Quintiles, UCB Group. PT is an independent Committee Member for clinical trial Data Safety Monitoring Boards for FDA approved trials for UCB Biopharma GmbH & SPRL, Parexel International, Prahealth Sciences and the Reformulary Group. PT is an advisory board member for the Canadian Reformulary Group Inc., a company that reviews the evidence for health insurance companies employer drug plans. Address correspondence to Dorcas Beaton BScOT, PhD, Senior Scientist, Institute for Work & Health, 481 University Avenue, Toronto, ON Canada. Email: dbeaton@iwh.on.ca
Maarten de Wit
Institute for Work & Health and Institute for Health Policy Management and Evaluation, University of Toronto, Toronto ON Canada; Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, ON, Canada; Centre for Practice-Changing Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada; University of Ottawa, Ottawa, ON, Canada; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada; Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, 92100 Boulogne-Billancourt; INSERM U1173, Laboratoire d’Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, 78180 Saint-Quentin en Yvelines; France Department of Medical Humanities, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands; Sorbonne Université, Paris France; Pitié Salpêtrière hospital, APHP, Rheumatology department, Paris, France; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St Leonards, Australia; Medicine Service, VA Medical Center, Birmingham, AL , USA; Department of Medicine, School of Medicine, University of Alabama, Birmingham, AL, USA; Division of Epidemiology, School of Public Health, University of Alabama, Birmingham, AL, USA SDG LLC, Cambridge, MA, USA; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto CA, USA; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health , Faculty of Medicine, University of Ottawa ; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada. In kind support from Knowledge Transfer and Exchange team and the Measurement Sciences group at the Institute for Work & Health is acknowledged for the development of the OMERACT Way graphics and input into the methods used. PGC is funded in part by the National Institute of Health Research (NIHR) Leeds Biomedical Research Centre. This article presents independent research funded by the NIHR. The views expressed are those of the authors and not necessarily those of the National Health Services (NHS), the NIHR or the Department of Health. JAS has received consultant fees from Crealta/Horizon, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the University of Alabama Birmingham (UAB) Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS served as a member of the American College of Rheumatology's (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and the co-chair of the ACR Criteria and Response Criteria subcommittee. LMM is a Principal Investigator on the Australian Rheumatology Association Database that has received arms-length funding from 4 companies (Abbvie Australasia Ltd, Pfizer Australia, Janssen Australia, Eli Lilly Australia). PT is [unpaid] Chair of the Management SubCommittee of the Executive committee of a registered non-profit independent medical research organization, OMERACT, whose goal is to improve and advance the health outcomes for patients suffering from musculoskeletal conditions. OMERACT receives unrestricted educational grants from the American College of Rheumatology, European League of Rheumatology and several pharmaceutical companies listed below which is used to support fellows, international patient groups and support a major international biennial conference which results in many peer reviewed publications; Abbvie Amgen, Astra Zeneca, Bristol Myers Squibb, Celgene, Centrexion, EliLilly, Genentech/Roche, Gruenthal, Horizon Pharma Inc., Janssen, Novartis, Pfizer, Quintiles, UCB Group. PT is an independent Committee Member for clinical trial Data Safety Monitoring Boards for FDA approved trials for UCB Biopharma GmbH & SPRL, Parexel International, Prahealth Sciences and the Reformulary Group. PT is an advisory board member for the Canadian Reformulary Group Inc., a company that reviews the evidence for health insurance companies employer drug plans. Address correspondence to Dorcas Beaton BScOT, PhD, Senior Scientist, Institute for Work & Health, 481 University Avenue, Toronto, ON Canada. Email: dbeaton@iwh.on.ca
Laure Gossec
Institute for Work & Health and Institute for Health Policy Management and Evaluation, University of Toronto, Toronto ON Canada; Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, ON, Canada; Centre for Practice-Changing Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada; University of Ottawa, Ottawa, ON, Canada; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada; Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, 92100 Boulogne-Billancourt; INSERM U1173, Laboratoire d’Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, 78180 Saint-Quentin en Yvelines; France Department of Medical Humanities, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands; Sorbonne Université, Paris France; Pitié Salpêtrière hospital, APHP, Rheumatology department, Paris, France; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St Leonards, Australia; Medicine Service, VA Medical Center, Birmingham, AL , USA; Department of Medicine, School of Medicine, University of Alabama, Birmingham, AL, USA; Division of Epidemiology, School of Public Health, University of Alabama, Birmingham, AL, USA SDG LLC, Cambridge, MA, USA; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto CA, USA; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health , Faculty of Medicine, University of Ottawa ; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada. In kind support from Knowledge Transfer and Exchange team and the Measurement Sciences group at the Institute for Work & Health is acknowledged for the development of the OMERACT Way graphics and input into the methods used. PGC is funded in part by the National Institute of Health Research (NIHR) Leeds Biomedical Research Centre. This article presents independent research funded by the NIHR. The views expressed are those of the authors and not necessarily those of the National Health Services (NHS), the NIHR or the Department of Health. JAS has received consultant fees from Crealta/Horizon, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the University of Alabama Birmingham (UAB) Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS served as a member of the American College of Rheumatology's (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and the co-chair of the ACR Criteria and Response Criteria subcommittee. LMM is a Principal Investigator on the Australian Rheumatology Association Database that has received arms-length funding from 4 companies (Abbvie Australasia Ltd, Pfizer Australia, Janssen Australia, Eli Lilly Australia). PT is [unpaid] Chair of the Management SubCommittee of the Executive committee of a registered non-profit independent medical research organization, OMERACT, whose goal is to improve and advance the health outcomes for patients suffering from musculoskeletal conditions. OMERACT receives unrestricted educational grants from the American College of Rheumatology, European League of Rheumatology and several pharmaceutical companies listed below which is used to support fellows, international patient groups and support a major international biennial conference which results in many peer reviewed publications; Abbvie Amgen, Astra Zeneca, Bristol Myers Squibb, Celgene, Centrexion, EliLilly, Genentech/Roche, Gruenthal, Horizon Pharma Inc., Janssen, Novartis, Pfizer, Quintiles, UCB Group. PT is an independent Committee Member for clinical trial Data Safety Monitoring Boards for FDA approved trials for UCB Biopharma GmbH & SPRL, Parexel International, Prahealth Sciences and the Reformulary Group. PT is an advisory board member for the Canadian Reformulary Group Inc., a company that reviews the evidence for health insurance companies employer drug plans. Address correspondence to Dorcas Beaton BScOT, PhD, Senior Scientist, Institute for Work & Health, 481 University Avenue, Toronto, ON Canada. Email: dbeaton@iwh.on.ca
Lyn M. March
Institute for Work & Health and Institute for Health Policy Management and Evaluation, University of Toronto, Toronto ON Canada; Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, ON, Canada; Centre for Practice-Changing Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada; University of Ottawa, Ottawa, ON, Canada; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada; Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, 92100 Boulogne-Billancourt; INSERM U1173, Laboratoire d’Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, 78180 Saint-Quentin en Yvelines; France Department of Medical Humanities, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands; Sorbonne Université, Paris France; Pitié Salpêtrière hospital, APHP, Rheumatology department, Paris, France; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St Leonards, Australia; Medicine Service, VA Medical Center, Birmingham, AL , USA; Department of Medicine, School of Medicine, University of Alabama, Birmingham, AL, USA; Division of Epidemiology, School of Public Health, University of Alabama, Birmingham, AL, USA SDG LLC, Cambridge, MA, USA; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto CA, USA; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health , Faculty of Medicine, University of Ottawa ; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada. In kind support from Knowledge Transfer and Exchange team and the Measurement Sciences group at the Institute for Work & Health is acknowledged for the development of the OMERACT Way graphics and input into the methods used. PGC is funded in part by the National Institute of Health Research (NIHR) Leeds Biomedical Research Centre. This article presents independent research funded by the NIHR. The views expressed are those of the authors and not necessarily those of the National Health Services (NHS), the NIHR or the Department of Health. JAS has received consultant fees from Crealta/Horizon, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the University of Alabama Birmingham (UAB) Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS served as a member of the American College of Rheumatology's (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and the co-chair of the ACR Criteria and Response Criteria subcommittee. LMM is a Principal Investigator on the Australian Rheumatology Association Database that has received arms-length funding from 4 companies (Abbvie Australasia Ltd, Pfizer Australia, Janssen Australia, Eli Lilly Australia). PT is [unpaid] Chair of the Management SubCommittee of the Executive committee of a registered non-profit independent medical research organization, OMERACT, whose goal is to improve and advance the health outcomes for patients suffering from musculoskeletal conditions. OMERACT receives unrestricted educational grants from the American College of Rheumatology, European League of Rheumatology and several pharmaceutical companies listed below which is used to support fellows, international patient groups and support a major international biennial conference which results in many peer reviewed publications; Abbvie Amgen, Astra Zeneca, Bristol Myers Squibb, Celgene, Centrexion, EliLilly, Genentech/Roche, Gruenthal, Horizon Pharma Inc., Janssen, Novartis, Pfizer, Quintiles, UCB Group. PT is an independent Committee Member for clinical trial Data Safety Monitoring Boards for FDA approved trials for UCB Biopharma GmbH & SPRL, Parexel International, Prahealth Sciences and the Reformulary Group. PT is an advisory board member for the Canadian Reformulary Group Inc., a company that reviews the evidence for health insurance companies employer drug plans. Address correspondence to Dorcas Beaton BScOT, PhD, Senior Scientist, Institute for Work & Health, 481 University Avenue, Toronto, ON Canada. Email: dbeaton@iwh.on.ca
Lee S. Simon
Institute for Work & Health and Institute for Health Policy Management and Evaluation, University of Toronto, Toronto ON Canada; Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, ON, Canada; Centre for Practice-Changing Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada; University of Ottawa, Ottawa, ON, Canada; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada; Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, 92100 Boulogne-Billancourt; INSERM U1173, Laboratoire d’Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, 78180 Saint-Quentin en Yvelines; France Department of Medical Humanities, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands; Sorbonne Université, Paris France; Pitié Salpêtrière hospital, APHP, Rheumatology department, Paris, France; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St Leonards, Australia; Medicine Service, VA Medical Center, Birmingham, AL , USA; Department of Medicine, School of Medicine, University of Alabama, Birmingham, AL, USA; Division of Epidemiology, School of Public Health, University of Alabama, Birmingham, AL, USA SDG LLC, Cambridge, MA, USA; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto CA, USA; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health , Faculty of Medicine, University of Ottawa ; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada. In kind support from Knowledge Transfer and Exchange team and the Measurement Sciences group at the Institute for Work & Health is acknowledged for the development of the OMERACT Way graphics and input into the methods used. PGC is funded in part by the National Institute of Health Research (NIHR) Leeds Biomedical Research Centre. This article presents independent research funded by the NIHR. The views expressed are those of the authors and not necessarily those of the National Health Services (NHS), the NIHR or the Department of Health. JAS has received consultant fees from Crealta/Horizon, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the University of Alabama Birmingham (UAB) Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS served as a member of the American College of Rheumatology's (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and the co-chair of the ACR Criteria and Response Criteria subcommittee. LMM is a Principal Investigator on the Australian Rheumatology Association Database that has received arms-length funding from 4 companies (Abbvie Australasia Ltd, Pfizer Australia, Janssen Australia, Eli Lilly Australia). PT is [unpaid] Chair of the Management SubCommittee of the Executive committee of a registered non-profit independent medical research organization, OMERACT, whose goal is to improve and advance the health outcomes for patients suffering from musculoskeletal conditions. OMERACT receives unrestricted educational grants from the American College of Rheumatology, European League of Rheumatology and several pharmaceutical companies listed below which is used to support fellows, international patient groups and support a major international biennial conference which results in many peer reviewed publications; Abbvie Amgen, Astra Zeneca, Bristol Myers Squibb, Celgene, Centrexion, EliLilly, Genentech/Roche, Gruenthal, Horizon Pharma Inc., Janssen, Novartis, Pfizer, Quintiles, UCB Group. PT is an independent Committee Member for clinical trial Data Safety Monitoring Boards for FDA approved trials for UCB Biopharma GmbH & SPRL, Parexel International, Prahealth Sciences and the Reformulary Group. PT is an advisory board member for the Canadian Reformulary Group Inc., a company that reviews the evidence for health insurance companies employer drug plans. Address correspondence to Dorcas Beaton BScOT, PhD, Senior Scientist, Institute for Work & Health, 481 University Avenue, Toronto, ON Canada. Email: dbeaton@iwh.on.ca
Jasvinder A. Singh
Institute for Work & Health and Institute for Health Policy Management and Evaluation, University of Toronto, Toronto ON Canada; Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, ON, Canada; Centre for Practice-Changing Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada; University of Ottawa, Ottawa, ON, Canada; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada; Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, 92100 Boulogne-Billancourt; INSERM U1173, Laboratoire d’Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, 78180 Saint-Quentin en Yvelines; France Department of Medical Humanities, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands; Sorbonne Université, Paris France; Pitié Salpêtrière hospital, APHP, Rheumatology department, Paris, France; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St Leonards, Australia; Medicine Service, VA Medical Center, Birmingham, AL , USA; Department of Medicine, School of Medicine, University of Alabama, Birmingham, AL, USA; Division of Epidemiology, School of Public Health, University of Alabama, Birmingham, AL, USA SDG LLC, Cambridge, MA, USA; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto CA, USA; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health , Faculty of Medicine, University of Ottawa ; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada. In kind support from Knowledge Transfer and Exchange team and the Measurement Sciences group at the Institute for Work & Health is acknowledged for the development of the OMERACT Way graphics and input into the methods used. PGC is funded in part by the National Institute of Health Research (NIHR) Leeds Biomedical Research Centre. This article presents independent research funded by the NIHR. The views expressed are those of the authors and not necessarily those of the National Health Services (NHS), the NIHR or the Department of Health. JAS has received consultant fees from Crealta/Horizon, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the University of Alabama Birmingham (UAB) Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS served as a member of the American College of Rheumatology's (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and the co-chair of the ACR Criteria and Response Criteria subcommittee. LMM is a Principal Investigator on the Australian Rheumatology Association Database that has received arms-length funding from 4 companies (Abbvie Australasia Ltd, Pfizer Australia, Janssen Australia, Eli Lilly Australia). PT is [unpaid] Chair of the Management SubCommittee of the Executive committee of a registered non-profit independent medical research organization, OMERACT, whose goal is to improve and advance the health outcomes for patients suffering from musculoskeletal conditions. OMERACT receives unrestricted educational grants from the American College of Rheumatology, European League of Rheumatology and several pharmaceutical companies listed below which is used to support fellows, international patient groups and support a major international biennial conference which results in many peer reviewed publications; Abbvie Amgen, Astra Zeneca, Bristol Myers Squibb, Celgene, Centrexion, EliLilly, Genentech/Roche, Gruenthal, Horizon Pharma Inc., Janssen, Novartis, Pfizer, Quintiles, UCB Group. PT is an independent Committee Member for clinical trial Data Safety Monitoring Boards for FDA approved trials for UCB Biopharma GmbH & SPRL, Parexel International, Prahealth Sciences and the Reformulary Group. PT is an advisory board member for the Canadian Reformulary Group Inc., a company that reviews the evidence for health insurance companies employer drug plans. Address correspondence to Dorcas Beaton BScOT, PhD, Senior Scientist, Institute for Work & Health, 481 University Avenue, Toronto, ON Canada. Email: dbeaton@iwh.on.ca
Vibeke Strand
Institute for Work & Health and Institute for Health Policy Management and Evaluation, University of Toronto, Toronto ON Canada; Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, ON, Canada; Centre for Practice-Changing Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada; University of Ottawa, Ottawa, ON, Canada; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada; Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, 92100 Boulogne-Billancourt; INSERM U1173, Laboratoire d’Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, 78180 Saint-Quentin en Yvelines; France Department of Medical Humanities, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands; Sorbonne Université, Paris France; Pitié Salpêtrière hospital, APHP, Rheumatology department, Paris, France; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St Leonards, Australia; Medicine Service, VA Medical Center, Birmingham, AL , USA; Department of Medicine, School of Medicine, University of Alabama, Birmingham, AL, USA; Division of Epidemiology, School of Public Health, University of Alabama, Birmingham, AL, USA SDG LLC, Cambridge, MA, USA; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto CA, USA; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health , Faculty of Medicine, University of Ottawa ; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada. In kind support from Knowledge Transfer and Exchange team and the Measurement Sciences group at the Institute for Work & Health is acknowledged for the development of the OMERACT Way graphics and input into the methods used. PGC is funded in part by the National Institute of Health Research (NIHR) Leeds Biomedical Research Centre. This article presents independent research funded by the NIHR. The views expressed are those of the authors and not necessarily those of the National Health Services (NHS), the NIHR or the Department of Health. JAS has received consultant fees from Crealta/Horizon, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the University of Alabama Birmingham (UAB) Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS served as a member of the American College of Rheumatology's (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and the co-chair of the ACR Criteria and Response Criteria subcommittee. LMM is a Principal Investigator on the Australian Rheumatology Association Database that has received arms-length funding from 4 companies (Abbvie Australasia Ltd, Pfizer Australia, Janssen Australia, Eli Lilly Australia). PT is [unpaid] Chair of the Management SubCommittee of the Executive committee of a registered non-profit independent medical research organization, OMERACT, whose goal is to improve and advance the health outcomes for patients suffering from musculoskeletal conditions. OMERACT receives unrestricted educational grants from the American College of Rheumatology, European League of Rheumatology and several pharmaceutical companies listed below which is used to support fellows, international patient groups and support a major international biennial conference which results in many peer reviewed publications; Abbvie Amgen, Astra Zeneca, Bristol Myers Squibb, Celgene, Centrexion, EliLilly, Genentech/Roche, Gruenthal, Horizon Pharma Inc., Janssen, Novartis, Pfizer, Quintiles, UCB Group. PT is an independent Committee Member for clinical trial Data Safety Monitoring Boards for FDA approved trials for UCB Biopharma GmbH & SPRL, Parexel International, Prahealth Sciences and the Reformulary Group. PT is an advisory board member for the Canadian Reformulary Group Inc., a company that reviews the evidence for health insurance companies employer drug plans. Address correspondence to Dorcas Beaton BScOT, PhD, Senior Scientist, Institute for Work & Health, 481 University Avenue, Toronto, ON Canada. Email: dbeaton@iwh.on.ca
Peter Tugwell
Institute for Work & Health and Institute for Health Policy Management and Evaluation, University of Toronto, Toronto ON Canada; Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, ON, Canada; Centre for Practice-Changing Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada; University of Ottawa, Ottawa, ON, Canada; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada; Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, 92100 Boulogne-Billancourt; INSERM U1173, Laboratoire d’Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, 78180 Saint-Quentin en Yvelines; France Department of Medical Humanities, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands; Sorbonne Université, Paris France; Pitié Salpêtrière hospital, APHP, Rheumatology department, Paris, France; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St Leonards, Australia; Medicine Service, VA Medical Center, Birmingham, AL , USA; Department of Medicine, School of Medicine, University of Alabama, Birmingham, AL, USA; Division of Epidemiology, School of Public Health, University of Alabama, Birmingham, AL, USA SDG LLC, Cambridge, MA, USA; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto CA, USA; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health , Faculty of Medicine, University of Ottawa ; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada. In kind support from Knowledge Transfer and Exchange team and the Measurement Sciences group at the Institute for Work & Health is acknowledged for the development of the OMERACT Way graphics and input into the methods used. PGC is funded in part by the National Institute of Health Research (NIHR) Leeds Biomedical Research Centre. This article presents independent research funded by the NIHR. The views expressed are those of the authors and not necessarily those of the National Health Services (NHS), the NIHR or the Department of Health. JAS has received consultant fees from Crealta/Horizon, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the University of Alabama Birmingham (UAB) Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS served as a member of the American College of Rheumatology's (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and the co-chair of the ACR Criteria and Response Criteria subcommittee. LMM is a Principal Investigator on the Australian Rheumatology Association Database that has received arms-length funding from 4 companies (Abbvie Australasia Ltd, Pfizer Australia, Janssen Australia, Eli Lilly Australia). PT is [unpaid] Chair of the Management SubCommittee of the Executive committee of a registered non-profit independent medical research organization, OMERACT, whose goal is to improve and advance the health outcomes for patients suffering from musculoskeletal conditions. OMERACT receives unrestricted educational grants from the American College of Rheumatology, European League of Rheumatology and several pharmaceutical companies listed below which is used to support fellows, international patient groups and support a major international biennial conference which results in many peer reviewed publications; Abbvie Amgen, Astra Zeneca, Bristol Myers Squibb, Celgene, Centrexion, EliLilly, Genentech/Roche, Gruenthal, Horizon Pharma Inc., Janssen, Novartis, Pfizer, Quintiles, UCB Group. PT is an independent Committee Member for clinical trial Data Safety Monitoring Boards for FDA approved trials for UCB Biopharma GmbH & SPRL, Parexel International, Prahealth Sciences and the Reformulary Group. PT is an advisory board member for the Canadian Reformulary Group Inc., a company that reviews the evidence for health insurance companies employer drug plans. Address correspondence to Dorcas Beaton BScOT, PhD, Senior Scientist, Institute for Work & Health, 481 University Avenue, Toronto, ON Canada. Email: dbeaton@iwh.on.ca
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology
Dorcas E. Beaton, Lara J. Maxwell, Beverley J. Shea, George A. Wells, Maarten Boers, Shawna Grosskleg, Clifton O. Bingham, Philip G. Conaghan, Maria Antonietta D’Agostino, Maarten de Wit, Laure Gossec, Lyn M. March, Lee S. Simon, Jasvinder A. Singh, Vibeke Strand, Peter Tugwell
The Journal of Rheumatology Feb 2019, jrheum.181218; DOI: 10.3899/jrheum.181218
Accepted manuscript
Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology
Dorcas E. Beaton, Lara J. Maxwell, Beverley J. Shea, George A. Wells, Maarten Boers, Shawna Grosskleg, Clifton O. Bingham, Philip G. Conaghan, Maria Antonietta D’Agostino, Maarten de Wit, Laure Gossec, Lyn M. March, Lee S. Simon, Jasvinder A. Singh, Vibeke Strand, Peter Tugwell
The Journal of Rheumatology Feb 2019, jrheum.181218; DOI: 10.3899/jrheum.181218